Eliquent Japan, formerly known as IDEC, is a Japanese regulatory consulting company. We provide comprehensive regulatory services, market assessment service, licensing support service, etc. We are a part of ELIQUENT Life Sciences that creates an unprecedented assembly of global regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex global regulatory landscape. From thought to finish, concept to commerce, and strategy to execution— ELIQUENT Life Sciences is the singular regulatory resource that clients around the world trust. LEARN MORE about our strategic repositioning and integrated service offerings at eliquent.com Recently, we have created GPTs, “Japan Regulatory Insight,” that allow Q&A about newly issued regulatory notifications in Japan regarding the Japanese Phase 1 waiver and orphan drug designation, which have attracted much attention. If you are a ChatGPT Plus subscriber, please click the link below to use the GPTs "Japan Regulatory Insight."
https://chat.openai.com/g/g-D5L83iRSi-japan-regulatory-insight If you would like more detailed advice on your project than GPTs's general advice, please get in touch with Eliquent Japan!
